Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.52 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | CES2 | O00748 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | GALR3 | O60755 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CASP1 | P29466 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | CES1 | P23141 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29401981 | 1.00 | ALDH1A1 (0.52) | ALDH1A1ALOX15DGAT1KMT2ALMNA | |
| SCHEMBL321094 | 0.83 | DGAT1 (0.66) | ALDH1A1ALOX15DGAT1KMT2ALMNA | |
| SCHEMBL2554 | 0.81 | KDM4E (0.59) | ALDH1A1ALOX15DGAT1KMT2ALMNA | |
| SCHEMBL30722862 | 0.81 | KDM4E (0.59) | ALDH1A1ALOX15DGAT1KMT2ALMNA | |
| SCHEMBL31173096 | 0.80 | HPGD (0.50) | ALDH1A1ALOX15DGAT1KMT2ALMNA | |
| SCHEMBL16079246 | 0.79 | DGAT1 (0.41) | ALDH1A1ALOX15DGAT1KMT2ALMNA | |
| SCHEMBL20560643 | 0.79 | DGAT1 (0.41) | ALDH1A1ALOX15DGAT1KMT2ALMNA | |
| SCHEMBL351693 | 0.79 | DGAT1 (0.71) | ALDH1A1ALOX15DGAT1KMT2ALMNA | |
| SCHEMBL10082 | 0.79 | DGAT1 (0.50) | ALDH1A1ALOX15DGAT1KMT2ALMNA | |
| SCHEMBL30374539 | 0.79 | DGAT1 (0.50) | ALDH1A1ALOX15DGAT1KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 235 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111732594-B | Preparation method of fluxaparide | 苏州富士莱医药股份有限公司 | 2022-03-04 | — | — | CN | claimed |
| WO-2022036940-A1 | PREPARATION METHOD FOR FLUZOPARIB | 苏州富士莱医药股份有限公司 | 2022-02-24 | — | — | WO | claimed |
| CN-111732594-A | Preparation method of fluxaparide | 苏州富士莱医药股份有限公司 | 2020-10-02 | — | — | CN | claimed |
| EP-4725946-A1 | IRAK4 DEGRADATION AGENT AND USE THEREOF | Guangzhou Unirise Pharmaceutical Co., Ltd. (CN) | 2026-04-15 | — | — | EP | disclosed |
| WO-2024251040-A1 | IRAK4 DEGRADATION AGENT AND USE THEREOF | 广州市联瑞制药有限公司 | 2024-12-12 | — | — | WO | disclosed |
| CN-118480001-A | C-Kit (V559D)/PDGFR beta double-target allosteric inhibitor and preparation method, pharmaceutical composition and application thereof | 贵州省天然产物研究中心 | 2024-08-13 | — | — | CN | disclosed |
| US-12018007-B2 | Method for manufacturing diarylmethane compound | TOKUYAMA CORPORATION (JP) | 2024-06-25 | — | — | US | disclosed |
| US-12018007-B2 | Method for manufacturing diarylmethane compound | TOKUYAMA CORPORATION (JP) | 2024-06-25 | — | — | US | disclosed |
| US-20230303570-A1 | KINASE INHIBITORS AND USES THEREOF | ABM THERAPEUTICS CORP (US) | 2023-09-28 | — | — | US | disclosed |
| US-20230286981-A1 | Imidazo[4,5-c]quinolin-2-one Compounds and Their Use in Treating Cancer | ASTRAZENECA AB (SE) | 2023-09-14 | — | — | US | disclosed |
| US-20230286981-A1 | Imidazo[4,5-c]quinolin-2-one Compounds and Their Use in Treating Cancer | ASTRAZENECA AB (SE) | 2023-09-14 | — | — | US | disclosed |
| EP-1463505-A2 | 3-(PHENYL-ALKOXY)-5-(PHENYL)-PYRIDINE DERIVATIVES AND RELATED COMPOUNDS AS KINASE INHIBITORS FOR THE TREATMENT OF CANCER | Abbott Laboratories (US) | 2004-10-06 | — | — | EP | disclosed |
| EP-1379525-A2 | HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | NPS PHARMACEUTICALS, INC. (US) | 2004-01-14 | — | — | EP | disclosed |
| US-6660753-B2 | For therapy of stroke, head trauma, anoxic injury, ischemic injury, hypoglycemia, epilepsy, pain, migraine headaches, Parkinson's disease, senile dementia, Huntington's Chorea, anxiety, and Alzheimer's disease | NPS PHARMACEUTICALS, INC. | 2003-12-09 | — | — | US | disclosed |
| US-20030199511-A1 | Kinase inhibitors | ABBVIE INC. | 2003-10-23 | — | — | US | disclosed |
| US-20030187026-A1 | Kinase inhibitors | ABBOTT LABORATORIES | 2003-10-02 | — | — | US | disclosed |
| WO-2003051366-A2 | 3-(PHENYL-ALKOXY)-5-(PHENYL)-PYRIDINE DERIVATIVES AND RELATED COMPOUNDS AS KINASE INHIBITORS FOR THE TREATMENT OF CANCER | ABBOTT LABORATORIES (US) | 2003-06-26 | — | — | WO | disclosed |
| US-20030055085-A1 | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | ASTRAZENECA AB (SE) | 2003-03-20 | — | — | US | disclosed |
| WO-2002068417-A3 | HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | SLASSI ABDELMALIK (CA) | 2002-11-14 | — | — | WO | disclosed |
| WO-2002068417-A2 | HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | NPS PHARMACEUTICALS, INC. (US) | 2002-09-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303570-A1 | KINASE INHIBITORS AND USES THEREOF | ERBB2, ERBB3, ERBB4 | ALDH1A1 1859/4885ALOX15 3731/4885DGAT1 4818/4885 |
| US-20030187026-A1 | Kinase inhibitors | MAP3K20, MAP3K19, MAP3K1 | ALDH1A1 3292/4885ALOX15 4082/4885DGAT1 3473/4885 |
| US-12018007-B2 | Method for manufacturing diarylmethane compound | GLP1R, IAPP, ARRB1 | ALDH1A1 252/4885ALOX15 2243/4885DGAT1 767/4885 |
| US-20030199511-A1 | Kinase inhibitors | MAP3K20, MAP3K19, MAP3K1 | ALDH1A1 3292/4885ALOX15 4082/4885DGAT1 3473/4885 |
| US-20030055085-A1 | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | GRM2, GRIN2A, GRM1 | ALDH1A1 3466/4885ALOX15 2672/4885DGAT1 1950/4885 |
| US-20230286981-A1 | Imidazo[4,5-c]quinolin-2-one Compounds and Their Use in Treating Cancer | ATM, BRCA1, CHEK2 | ALDH1A1 1324/4885ALOX15 4860/4885DGAT1 4514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.